<DOC>
	<DOCNO>NCT00738738</DOCNO>
	<brief_summary>This open-label , multi-site , 6-month study investigational compound elderly outpatient , age 65 year old , assess long-term safety tolerability compound treatment elderly subject Generalized Anxiety Disorder ( GAD ) .</brief_summary>
	<brief_title>6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder ( GAD )</brief_title>
	<detailed_description>Termination reason : On February 23rd 2009 , decision terminate development PD 0332334 communicate investigator study . The decision terminate study base safety concern .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<criteria>Men woman age &gt; 65 year . A primary diagnosis Generalized Anxiety Disorder accord Diagnostic Statistical ManualIV ( DSMIV ) . Subjects must HAMA score 16 high screening baseline visit . Women pregnant contemplating pregnancy ( eg , via vitro fertilization ) study 30 day last dose study medication . Subjects evidence current ( within past 6 month ) clinically significant unstable hematological , autoimmune , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , pancreatic , psychiatric , neurologic , immunological retinal disorder ; subject active infection within past 2 month . Subjects ongoing , unresolved , clinically significant cardiovascular cerebrovascular medical problem . Mini Mental Status Exam ( MMSE ) score &lt; 24 possibility undiagnosed dementia , cognitive amnestic disorder , include , limited mild cognitive impairment .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Generalized Anxiety Disorder Elderly</keyword>
</DOC>